General NAFLD & NASH

​​​​​​

​Thursday June 1​

Session 1a: Introduction - Lecture
16:00-17:30
Hall A​

Introduction of the Program and its Objectives

Arun J. Sanyal (USA); Rifaat Safadi (Israel); Quentin M. Anstee (UK)

Session 1b: NAFLD the Big Picture - Panel Discussion
16:00-17:30
Hall A​

Histological Definition of NAFLD
Pierre Bedossa (France)
Clinical-laboratory Assessment of NAFLD
Puneet Puri (USA)
Imaging and Elastography-based Approaches
Laurent Castera (France)
Best Practices in Disease Assessment in Daily Care
Mary Rinella (USA) 


Session 3: Recognizing NAFLD in Your Practice - Panel Discussion
18:00-19:30
Hall A​

Why Should You Care about NAFLD?
Quentin M. Anstee (UK)
How Common is NASH in your Diabetes Clinic?
Elisabetta Bugianesi (Italy)
How Common is NASH in Primary Care?
Stephen A. Harrison (USA) 


Opening Ceremony
19:30-21:00
Hall A​

Keynote Lecture - The social, economic and public health impact of obesity
Speaker to be announced


FRIDAY JUNE 2

​Session 5: Diabetes and NAFLD - Panel Discussion / Audience Questions and Answers
10:30-12:30
Hall A​

The Great Debate - Will NAFLD Become an Irrelevant Clinical Entity with Tight Glycemic Control?

Yes - Hannele Yki-Järvinen (Finland)
No - Speaker to be announced


Session 6: Drug Safety in a Primary Care Setting - Lecture
14:00-15:30
Hall A

NAFLD as a manifestation of DILI in HIV-infected population
Lawrence Serfaty (France)
Challenges in Assessment of DILI in Obese Diabetic Individuals
Raul J. Andrade (Spain)
Drug Induced Liver Injury & NAFLD - Do’s and Don’ts of Medical Therapy
Arie Regev (USA)



Saturday June 3​

Session 8: Liver-related Outcomes in NAFLD - Audience Questions and Answers
08:00-09:30
Hall A​

NAFLD and liver cancer
Jean-Francois Dufour (Switzerland)

The Bidirectional Evolution of NAFLD
Arun J. Sanyal (USA)

The Great Debate - Is it Time to Drop Liver Histology as the Anchor for Assessment of NAFLD Evolution? 

Yes -Speaker to be announced
No - Pierre Bedossa (France) 


Session 10: What to do When You Find the Disease: Behavior Modification - Lecture
13:30-15:30
Hall A

Managing the Low Risk Patient…Providing Practical Advice Regarding Diet
and Exercise – Hepatologist Perspective
Manuel Romero Gomez (Spain)
Managing the Low Risk Patient…Providing Practical Advice Regarding Diet
and Exercise – Nutritionist Perspective
Shira Zelber Sagi (Israel)
Food Addiction, Impulsivity and Eating Disorders in Patients with NAFLD
Gerry Moeller (USA)
Alcohol Consumption in the Obese Diabetic Subject- How Much or How Little 
Ramon Bataller (USA) 


Session 11: Therapeutic Landscape for NASH - Panel Discussion
16:00-18:00
Hall A

Chair: Manuel Romero Gomez (Spain)

Current Compounds in Pivotal Trials
Vlad Ratziu (France)
Targets Under Evaluation in Early Phase Trials
Quentin M. Anstee (UK)
Drugs You Can Use in Your Office Today
Arun Sanyal (USA)
Bariatric Surgery-What is its Role
Rifaat Safadi (Israel) 

yellow_preliminary-scientific-program.jpg


Keep Me Updated


​​​ ​​​​​ ​​​​​ ​​​​​